Membranous nephropathy is a glomerular kidney disease characterized by immune-mediated thickening of the glomerular basement membrane and nephrotic-range proteinuria. It may be primary autoimmune disease or secondary to infections, autoimmune conditions, medications, or malignancy.
Phase 3 trials demonstrate atrasentan slows kidney function decline in IgA nephropathy patients, while obinutuzumab achieves superior remission rates in primary membranous nephropathy compared to standard treatment.
Roche announced that Gazyva/Gazyvaro met its primary endpoint in the Phase III MAJESTY study for primary membranous nephropathy, showing statistically significant complete remission rates versus tacrolimus. The drug could become the first approved therapy for this rare autoimmune kidney disease.
Genentech's Phase III MAJESTY study showed Gazyva achieved statistically significant complete remission rates versus tacrolimus in primary membranous nephropathy, a chronic autoimmune kidney disease affecting over 96,000 people in the U.S.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07535138 |
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07416942 |
Omics of Rituximab-resistance |
NOT_YET_RECRUITING | |
| NCT07389499 |
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07038382 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis |
RECRUITING | PHASE2 |
| NCT06994468 |
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy |
COMPLETED | NA |
| NCT06760845 |
Raman Spectroscopy Diagnosis of Kidney Diseases |
RECRUITING | |
| NCT06690359 |
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT06341205 |
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) |
RECRUITING | PHASE3 |
| NCT06315504 |
Circulating Factors in Nephrotic Syndrome |
NOT_YET_RECRUITING | |
| NCT06242327 |
An Outcome Analysis of Primary Membranous Nephropathy |
RECRUITING |
